MedPath

SONESCENCE INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

1 Phases

Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 2
1 (100.0%)

Phase 2 Randomized Study to Compare Ultrasonic Drug Delivery to Standard of Care for the Treatment of Infections in Non-Healing Wounds

Phase 2
Conditions
Non-healing Wound
Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Interventions
Combination Product: Ultrasonic Drug Delivery
Drug: Standard of Care Antibiotic Treatment
First Posted Date
2018-11-06
Last Posted Date
2018-11-06
Lead Sponsor
Sonescence, Inc.
Target Recruit Count
30
Registration Number
NCT03732365

Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion

Conditions
Infection, Soft Tissue
Infection, Wound
Cellulitis
Diabetic Foot Ulcer
First Posted Date
2010-11-10
Last Posted Date
2018-10-23
Lead Sponsor
Sonescence, Inc.
Registration Number
NCT01238276
Locations
🇺🇸

Sonoma West Medical Center, Sebastopol, California, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath